V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 597-602

  Bernat, A ^a   Hoffmann, P ^a   Dumas, A ^a   Serradeil Le Gal, C ^a   Raufaste, D ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN DERIVATIVE; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; FOROPAFANT; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; OXYTOCIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RELCOVAPTAN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO]; BLOOD CLOTTING FACTOR; CELL SURFACE RECEPTOR; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; THIAZOLE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; URINARY TRACT AGENT; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOG; DOSE RESPONSE; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY MEDULLA; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; ANIMAL; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANIMALS; BLOOD COAGULATION FACTORS; DEAMINO ARGININE VASOPRESSIN; DOGS; KIDNEY MEDULLA; MALE; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, VASOPRESSIN; RENAL AGENTS; THIAZOLES;

EID: 0030611357     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. ABREG, M., NILSSON, I. M. AND VILHARDT, H.: The release of fibrinolytic activator and factor VIII after injection of DDAVP. In Progress in Chemical Fibrinolysis and Thrombolysis, ed. by J. F. Davidson, pp. 92-97, Edinburgh/London/ New York, Churchill Livingstone, 1979.
2. AMMAR, A., RAJERISON, R. M., ROSEAU, S., BLOCH-FAURE, M. AND BUTLEN D.: Frog glomerular vasotocin receptors resemble mammalian V1b receptors. Am. J. Physiol. 267: R1198-R1208, 1994.
3. BICHET, D. G., RAZI, M., LONERGAN, M., ARTHUS, M. F., PAPUKNA, V., KORTAS, C. AND BARJON, J. N.: Hemodynamic and coagulation responses to 1-desamino(8-D-arginine)vasopressin in patients with congenital nephrogenic diabetes insipidus. N. Engl. J. Med. 318: 881-887, 1988.
4. BIRNBAUMER, M., SEIBOLD, A., GILBERT, S., ISHIDO, M., BARBERIS, C., ANTARAMIAN, A., BRADET, P. AND ROSENTHAL, W.: Molecular cloning of the receptor for human antidiuretic hormone. Nature (Lond.) 357: 333-335, 1992.
5. BOVE, C. M., CASEY, B. AND MARDER, V. J.: DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb. Haemost. 75: 471-475, 1996.
6. BRADFORD, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
7. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
8. FLORDAL, P. A. AND SAHLIN, S.: Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br. J. Surg. 80: 723-724, 1993.
9. FUJISAWA, G., ISHIKAWA, S., TSUBOI, Y., OKADA, K. AND SAITO, T.: Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int. 44: 19-23, 1993.
10. 2 [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. Eur. J. Biochem. 215: 1-7, 1993.
11. GUILLON, G., BUTLEN, D., CANTAU, B., BARTH, T. AND JARD, S.: Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: Relation of adenylate cyclase activation. Eur. J. Pharmacol. 85: 291-304, 1982.
12. HASHEMI, S., PALMER, D. S., AYE, M. T. AND GANZ, P. R.: Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J. Cell. Physiol. 154: 496-450, 1993.
13. HERBERT, J. M., BERNAT, A., VALETTE, G., GIGO, V., LALE, A., LAPLACE, M. C., LESPY, L., SAVI, P., MAFFRAND, J. P. AND LE FUR, G.: Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J. Pharmacol. Exp. Ther. 259: 44-51, 1991.
14. HOFBAUER, K. G., MAH, S. C. AND OPPERMAN, J. R.: Chronic blockade of vasopressin receptor in rats. J. Cardiovasc. Pharmacol. 8: S56-S60, 1986.
15. JOHNSON, G. S., KRAUS, K. H., TURRENTINE, M. A. AND DEAN, P. W.: DDAVP-induced increases in coagulation factor VIII and von Willebrand factor in the plasma of conscious dogs. J. Vet. Pharmacol. Thr. 9: 370-375, 1986.
16. JOHNSTONE, M. T., ANDREWS, T., WARE, J. A., RUDD, M. A., GEORGE, D., WEINSTEIN, M. AND LOSCALZO, J.: Bleeding time prolongation with streptokinase and its reduction with 1-deamino-8-D-arginine vasopressin. Circulation. 82: 2142-2151, 1990.
17. KINTER, L. B., MCCONNELL, I., GOODWIN, B., CAMPBELL, S., HUFFMAN, W., ARTHUS, M. F., LONERGAN, M. AND BICHET, D. G.: Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macca mulatta). J. Pharmacol. Exp. Ther. 261: 462-469, 1992.
18. KOBRINSKY, N. L., DOYLE, J. J. AND ISRAELS, E. D.: Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus. Lancet 1: 1293-1294, 1985.
19. LETHAGEN, S.: Desmopressin (DDAVP) and haemostasis. Ann. Hematol. 69: 173-180, 1994.
20. 2 receptors in dogs. Am. J. Physiol. 263: H188-H1891, 1992.
21. 2 receptor and possible link to nephrogenic diabetes insipidus. Nature (Lond.) 357: 336-339, 1994.
22. MANNING, M., NAWROCKA, E., MISICKA, A., OLMA, A. AND KLIS, W. A.: Potent and selective antagonists of the antidiuretic responses to arginine vasopressin based on modifications of [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid)2-D-leucine, 4-valine]arginine vasopressin at position 4. J. Med. Chem. 27: 423-429, 1984.
23. MANNUCCI, P. M., ABERG, M., NILSSON, I. M. AND ROBERTSON, B.: Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br. J. Haematol. 30: 81-93, 1975.
24. MANNUCCI, P. M., RUGGERI, Z. M., PARETI, F. I. AND CAPITANI, O. A.: 1-Deamino-8-DDAVP: A new pharmacological approach to the management of haemophilia and in Willebrand's disease? Lancet 1 (8017): 869-872, 1977 Apr. 23.
25. MUNSON, P. V. AND RODBARD, D.: LIGAND: A versatile computerized approavch for characterization of ligand-binding systems. Anal. Biochem. 107: 220-239, 1980.
26. SCHWARTZ, J., DERDOWSKA, I., SOBOCINSKA, M. AND KUPRYZEWSKI, G.: A potent new synthetic analog of vasopressin with relative agonist specificity for the pituitary. Endocrinology 129: 1107-1109, 1991.
27. 1a receptors. J. Clin. Invest. 92: 224-231, 1993.
28. 2 receptor antagonist. J. Clin. Invest. 98: 2729-2738, 1996.
29. SHULMAN, S. AND JOHNSON, H.: Heparin, DDAVP and bleeding time. Thromb. Haemost. 65: 242-244, 1991.
30. STASSEN, F. L., ERICKSON, R. W., HUFFMAN, W. F., STEFANKIEWICZ, J., SULAT, L. AND WIEBELHAUS, V. D.: Molecular mechanisms of novel antidiuretic antagonist: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. J. Pharmacol. Exp. Ther. 223: 50-54, 1982.
31. 2 vasopressin receptors. FEBS Lett. 362: 19-23, 1995.
32. VILHARDT, H. AND BARTH, T.: The release of factor VIII and tissue plasminogen activator cannot be blocked by specific antagonists to vasopressin. J. Recept. Res. 11: 239-245, 1991.
33. WUN, T., PAGLIERO, T. G. AND LACHANT, N. A.: Desmopressin stimulates the expression of P-selectin on human platelets in vitro. J. Lab. Clin. Med. 125: 401-409, 1995.
34. 2 receptor antagonist. Br. J. Pharmacol. 105: 787-791, 1992.